vs

Side-by-side financial comparison of Crane Co (CR) and Dexcom (DXCM). Click either name above to swap in a different company.

Dexcom is the larger business by last-quarter revenue ($1.3B vs $696.4M, roughly 1.8× Crane Co). Dexcom runs the higher net margin — 21.2% vs 9.6%, a 11.6% gap on every dollar of revenue. On growth, Crane Co posted the faster year-over-year revenue change (24.9% vs 21.6%). Over the past eight quarters, Crane Co's revenue compounded faster (14.8% CAGR vs 12.0%).

Crane Co. is an American industrial products company based in Stamford, Connecticut. Founded by Richard Teller Crane in 1855, it became one of the leading manufacturers of bathroom fixtures in the United States, until 1990, when that division was sold off. In 1960 it began the process of becoming a holding company with a diverse portfolio. Its business segments are Aerospace & Electronics, Engineered Materials, Fluid Handling, and Controls. Industries served by these segments include chemical...

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

CR vs DXCM — Head-to-Head

Bigger by revenue
DXCM
DXCM
1.8× larger
DXCM
$1.3B
$696.4M
CR
Growing faster (revenue YoY)
CR
CR
+3.3% gap
CR
24.9%
21.6%
DXCM
Higher net margin
DXCM
DXCM
11.6% more per $
DXCM
21.2%
9.6%
CR
Faster 2-yr revenue CAGR
CR
CR
Annualised
CR
14.8%
12.0%
DXCM

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CR
CR
DXCM
DXCM
Revenue
$696.4M
$1.3B
Net Profit
$67.1M
$267.3M
Gross Margin
40.4%
62.9%
Operating Margin
14.4%
25.6%
Net Margin
9.6%
21.2%
Revenue YoY
24.9%
21.6%
Net Profit YoY
-37.3%
153.6%
EPS (diluted)
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CR
CR
DXCM
DXCM
Q1 26
$696.4M
$1.3B
Q4 25
$581.0M
$1.3B
Q3 25
$589.2M
$1.2B
Q2 25
$577.2M
$1.2B
Q1 25
$557.6M
$1.0B
Q4 24
$544.1M
$1.1B
Q3 24
$548.3M
$994.2M
Q2 24
$528.6M
$1.0B
Net Profit
CR
CR
DXCM
DXCM
Q1 26
$67.1M
$267.3M
Q4 25
$81.7M
$267.3M
Q3 25
$91.4M
$283.8M
Q2 25
$86.4M
$179.8M
Q1 25
$107.1M
$105.4M
Q4 24
$81.0M
$151.7M
Q3 24
$77.3M
$134.6M
Q2 24
$71.6M
$143.5M
Gross Margin
CR
CR
DXCM
DXCM
Q1 26
40.4%
62.9%
Q4 25
41.6%
62.9%
Q3 25
42.7%
60.5%
Q2 25
42.0%
59.5%
Q1 25
42.6%
56.9%
Q4 24
40.9%
58.9%
Q3 24
41.4%
59.7%
Q2 24
40.0%
62.4%
Operating Margin
CR
CR
DXCM
DXCM
Q1 26
14.4%
25.6%
Q4 25
17.5%
25.6%
Q3 25
20.1%
20.1%
Q2 25
17.8%
18.4%
Q1 25
18.1%
12.9%
Q4 24
15.8%
17.0%
Q3 24
18.1%
15.3%
Q2 24
16.9%
15.7%
Net Margin
CR
CR
DXCM
DXCM
Q1 26
9.6%
21.2%
Q4 25
14.1%
21.2%
Q3 25
15.5%
23.5%
Q2 25
15.0%
15.5%
Q1 25
19.2%
10.2%
Q4 24
14.9%
13.6%
Q3 24
14.1%
13.5%
Q2 24
13.5%
14.3%
EPS (diluted)
CR
CR
DXCM
DXCM
Q1 26
$0.67
Q4 25
$1.40
$0.67
Q3 25
$1.56
$0.70
Q2 25
$1.47
$0.45
Q1 25
$1.83
$0.27
Q4 24
$1.37
$0.37
Q3 24
$1.33
$0.34
Q2 24
$1.23
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CR
CR
DXCM
DXCM
Cash + ST InvestmentsLiquidity on hand
$355.4M
$917.7M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$2.1B
$2.7B
Total Assets
$4.1B
$6.3B
Debt / EquityLower = less leverage
0.57×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CR
CR
DXCM
DXCM
Q1 26
$355.4M
$917.7M
Q4 25
$506.5M
$917.7M
Q3 25
$388.2M
$1.8B
Q2 25
$332.2M
$1.2B
Q1 25
$435.1M
$904.9M
Q4 24
$306.7M
$606.1M
Q3 24
$258.2M
$621.2M
Q2 24
$229.3M
$939.2M
Total Debt
CR
CR
DXCM
DXCM
Q1 26
$1.2B
Q4 25
$1.1B
Q3 25
Q2 25
Q1 25
Q4 24
$247.0M
Q3 24
Q2 24
Stockholders' Equity
CR
CR
DXCM
DXCM
Q1 26
$2.1B
$2.7B
Q4 25
$2.1B
$2.7B
Q3 25
$2.0B
$2.7B
Q2 25
$1.9B
$2.6B
Q1 25
$1.8B
$2.3B
Q4 24
$1.6B
$2.1B
Q3 24
$1.6B
$2.0B
Q2 24
$1.5B
$2.4B
Total Assets
CR
CR
DXCM
DXCM
Q1 26
$4.1B
$6.3B
Q4 25
$3.9B
$6.3B
Q3 25
$2.5B
$7.5B
Q2 25
$2.5B
$7.3B
Q1 25
$2.6B
$6.8B
Q4 24
$2.6B
$6.5B
Q3 24
$2.7B
$6.4B
Q2 24
$2.5B
$6.8B
Debt / Equity
CR
CR
DXCM
DXCM
Q1 26
0.57×
Q4 25
0.56×
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CR
CR
DXCM
DXCM
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$-40.2M
FCF MarginFCF / Revenue
-5.8%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$361.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CR
CR
DXCM
DXCM
Q1 26
Q4 25
$205.8M
$294.0M
Q3 25
$130.2M
$659.9M
Q2 25
$105.0M
$303.0M
Q1 25
$-46.2M
$183.8M
Q4 24
$202.0M
$301.4M
Q3 24
$75.4M
$199.5M
Q2 24
$51.3M
$279.4M
Free Cash Flow
CR
CR
DXCM
DXCM
Q1 26
$-40.2M
Q4 25
$196.0M
$192.1M
Q3 25
$116.8M
$579.4M
Q2 25
$88.9M
$208.9M
Q1 25
$-60.4M
$96.8M
Q4 24
$188.2M
$176.8M
Q3 24
$67.3M
$88.3M
Q2 24
$44.6M
$213.3M
FCF Margin
CR
CR
DXCM
DXCM
Q1 26
-5.8%
Q4 25
33.7%
15.3%
Q3 25
19.8%
47.9%
Q2 25
15.4%
18.1%
Q1 25
-10.8%
9.3%
Q4 24
34.6%
15.9%
Q3 24
12.3%
8.9%
Q2 24
8.4%
21.2%
Capex Intensity
CR
CR
DXCM
DXCM
Q1 26
1.5%
Q4 25
1.7%
8.1%
Q3 25
2.3%
6.7%
Q2 25
2.8%
8.1%
Q1 25
2.5%
8.4%
Q4 24
2.5%
11.2%
Q3 24
1.5%
11.2%
Q2 24
1.3%
6.6%
Cash Conversion
CR
CR
DXCM
DXCM
Q1 26
Q4 25
2.52×
1.10×
Q3 25
1.42×
2.33×
Q2 25
1.22×
1.69×
Q1 25
-0.43×
1.74×
Q4 24
2.49×
1.99×
Q3 24
0.98×
1.48×
Q2 24
0.72×
1.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CR
CR

Process Flow Technologies$378.1M54%
Aerospace & Advanced Technologies$318.3M46%

DXCM
DXCM

Segment breakdown not available.

Related Comparisons